Responsibilities Perform fundamental research on pharmaceuticals and therapeutics; build detailed financial models and investment theses. Evaluate drug pipelines, regulatory pathways, clinical trial readouts, and commercial potential across small molecules, biologics, and cell and gene therapies. Track sector trends and regulatory developments across specialty pharma, biotechnology, rare disease, oncology, and immunology. Analyse patent expirations, biosimilar/generic competition, pricing dynamics, and reimbursement policy impacts. Produce research reports, company updates, and sector outlooks informing buy/sell/hold decisions. Present recommendations, conviction levels, and risk–reward profiles to portfolio managers and the wider investment team. Engage with management teams, physicians/KOLs, and expert networks; attend medical conferences and investor events. Collaborate on position sizing, monitor existing holdings, and source new opportunities within healthcare strategies. Contribute to ESG integration on drug pricing, access to medicines, and clinical trial ethics. Requirements 5–15 years’ experience in equity research, buy-side analysis, or portfolio management covering pharmaceuticals/therapeutics/biotech. Proven track record analysing drug development, regulatory processes, and commercial forecasting. Strong financial modelling and valuation skills; deep understanding of pharmaceutical business models. Knowledge of blockbuster drug economics, lifecycle management, and portfolio diversification across therapeutic areas. Comfort interpreting clinical data and navigating FDA/EMA pathways; strong grasp of competitive landscapes. Degree in life sciences, finance, economics, or related field; CFA, PhD, or relevant scientific credentials advantageous. Clear written and verbal communication, including presenting to investment audiences. Intellectual curiosity and independent thinking to challenge consensus with evidence-based views.